XCUR
- Exicure, Inc.
()
Overview
Company Summary
Exicure, Inc. (XCUR) is a biotechnology company that focuses on developing and commercializing nucleic acid-based therapeutics. The company is based in Skokie, Illinois, and was founded in 2011.
Exicure primarily utilizes a proprietary technology platform known as Spherical Nucleic Acids (SNAs) to design and develop therapeutic products. SNAs are nanoscale, three-dimensional structures composed of nucleic acids (specifically, DNA or RNA) arranged on a spherical core. This unique structure enhances the stability and cellular uptake of the nucleic acids, allowing for improved targeting and efficacy in various disease areas.
The company's core focus is on developing therapeutics for immune-mediated disorders, neurological diseases, and oncology. Exicure's pipeline includes candidates that target gene regulation to address conditions such as psoriasis, alopecia areata, and Netherton syndrome, as well as neurodegenerative disorders like Huntington's disease. Additionally, the company is exploring SNA-based immunotherapies for the treatment of cancer.
Exicure's approach to therapeutics differs from traditional small molecules or protein-based drugs. Instead, it leverages the power of nucleic acids to interact directly with genes, potentially offering more precise and targeted treatments. The company's technology platform is also being explored for various applications beyond therapeutic development, including diagnostics and research tools.
To advance its pipeline candidates and expand its technology platform, Exicure collaborates with academic institutions, pharmaceutical companies, and other partners. The company aims to bring its SNA-based therapeutics to market and provide innovative treatment options for patients in need.